Pivot Bio
Provides gene-edited, nitrogen-producing soil microbes to farmers as a partial replacement for synthetic fertilizer.
Website: https://www.pivotbio.com/
PUBLIC
| Name | Pivot Bio |
| Tagline | Provides gene-edited, nitrogen-producing soil microbes to farmers as a partial replacement for synthetic fertilizer. |
| Headquarters | St. Louis, United States |
| Founded | 2011 |
| Stage | Series D+ |
| Business Model | B2B |
| Industry | Agtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | $100M+ (total disclosed ~$697M) |
Links
PUBLIC
- Website: https://www.pivotbio.com/
- LinkedIn: https://www.linkedin.com/company/pivot-bio/
- X / Twitter: https://twitter.com/pivotbio
Executive Summary
PUBLIC Pivot Bio has developed a commercial-scale biological alternative to synthetic nitrogen fertilizer, a wedge into the $200 billion global fertilizer market that combines agricultural necessity with environmental urgency [MIT News, Feb 2025]. Founded in 2011, the company engineers soil microbes to colonize plant roots and fix atmospheric nitrogen, directly delivering a key nutrient to crops while aiming to reduce the greenhouse gas emissions and water pollution associated with conventional fertilizer [Pivot Bio]. The founding team of Karsten Temme, Alvin Tamsir, and MIT professor Chris Voigt brought deep synthetic biology expertise to the challenge of nitrogen fixation, a foundational problem in agriculture that had largely been abandoned by commercial R&D [MIT News, Feb 2025].
Its first product for corn, PROVEN 40, launched in 2019 and has since been joined by offerings for wheat, cotton, and sorghum, forming a portfolio now used on millions of acres in the United States [AgFunderNews]. The company operates a classic B2B agricultural inputs model, selling directly to farmers, and crossed the $100 million revenue threshold in 2023 [J-WAFS, 2023]. With over $600 million in total capital raised, including a $430 million Series D in 2021, and a reported $2 billion valuation, Pivot Bio has secured the resources to scale manufacturing and distribution [Preqin, July 2021] [CNBC, May 2023]. The critical watchpoint for the next 12-18 months is the execution of its international expansion, particularly the ongoing work with smallholder farmers in Kenya, which will test the product's adaptability and unit economics outside its core U.S. row-crop market.
Data Accuracy: GREEN -- Core company facts, product claims, and funding details are confirmed by multiple independent sources including MIT News, Crunchbase, and Reuters.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series D+ |
| Business Model | B2B |
| Industry / Vertical | Agtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $100M+ (total disclosed ~$697,000,000) |
Company Overview
PUBLIC
Pivot Bio was founded in 2011 by a trio of scientists, Karsten Temme, Alvin Tamsir, and Chris Voigt, with the goal of engineering a biological alternative to synthetic nitrogen fertilizer [MIT News, Feb 2025]. The company is headquartered in St. Louis, a location that situates it within a major agricultural research and commercial hub. The founding premise was to harness naturally occurring microbes, which the company describes as having the inherent ability to fix atmospheric nitrogen, and reprogram them to reliably deliver nitrogen to the roots of cereal crops [Pivot Bio].
Key operational milestones followed a lengthy research and development phase. The company's first commercial product for corn, PROVEN, was launched in 2019 [AgFunderNews]. A significant inflection point came in July 2021 with a $430 million Series D financing round, which provided capital for scaling commercial operations and product development [Preqin, July 2021]. By 2023, the company reported its microbial products were used on more than 5 million acres of American farmland, and revenue surpassed $100 million for the first time [Agriculture Dive] [J-WAFS, 2023]. In a notable leadership transition, Chris Abbott was appointed CEO, replacing co-founder Karsten Temme, who moved into the role of Chief Innovation Officer [Agri-Pulse Communications].
Recent developments include the company's recognition on external lists, such as CNBC's Disruptor 50 in May 2023 and TIME's World's Top GreenTech Companies list for 2026 [CNBC, May 2023] [Pivot Bio]. The company also announced four new product launches in 2025 [Yahoo Finance].
Data Accuracy: GREEN -- Core founding and location details confirmed by the company website and MIT News. Major funding round and key commercial milestones corroborated by multiple independent news reports.
Product and Technology
MIXED Pivot Bio's commercial offering is a suite of crop-specific microbial inoculants, a biological input designed to integrate into existing farm operations rather than replace them entirely. The company's first product, PROVEN for corn, launched in 2019 and anchors the portfolio with a specific claim: it can replace up to 40 pounds of synthetic nitrogen per acre while maintaining yield [MIT News, Feb 2025]. This value proposition is delivered through gene-edited microbes that colonize plant roots and fix atmospheric nitrogen, delivering it directly to the crop as it grows [MIT News, Feb 2025]. The product line has since expanded to include formulations for corn silage, cotton, wheat, and sorghum, with four new product launches reported in 2025 [Pivot Bio] [Yahoo Finance].
Application is designed for ease of adoption, with PROVEN 40 available as either an on-seed treatment or an in-furrow liquid applied at planting [AgFunderNews]. The company emphasizes safety for the seed, user, and environment in its materials [Pivot Bio]. Beyond the core product, Pivot Bio operates the N-OVATOR® program, which allows farmers to earn sustainability credits for using its microbial nitrogen, creating a potential secondary revenue stream tied to environmental impact [Pivot Bio]. The underlying technology platform, though not detailed in public materials, appears to involve a proprietary process for identifying, optimizing, and manufacturing nitrogen-fixing microbial strains at commercial scale (inferred from job postings).
Data Accuracy: GREEN -- Product details, claims, and launch history are confirmed by the company website and multiple independent press reports.
Market Research
PUBLIC The market for agricultural biologicals, particularly nitrogen-fixing microbes, is being reshaped by a confluence of economic and environmental pressures that make synthetic fertilizer alternatives more compelling than ever.
A precise, third-party TAM/SAM/SOM breakdown for Pivot Bio's specific microbial nitrogen segment is not publicly available. However, the company's addressable market can be contextualized by the massive global synthetic nitrogen fertilizer market, which was valued at over $100 billion annually [Reuters, July 2021]. Pivot Bio's initial products target corn, wheat, cotton, and sorghum in the United States, a multi-billion dollar subset of this broader market. The company's stated goal is to replace a portion of the roughly 110 million tons of synthetic nitrogen applied globally each year [MIT News, Feb 2025].
Demand is driven by a volatile and often high cost base for petrochemical-derived fertilizers, which ties farm input expenses directly to natural gas prices and global supply chain shocks. Pivot Bio's microbial nitrogen offers a predictable, on-farm production cost that is decoupled from these commodity swings, a key selling point for farmer profitability [Pivot Bio]. Environmental regulation and consumer preferences are also creating tailwinds. Nitrate runoff from synthetic fertilizers is a major source of water pollution, and the production of these fertilizers is responsible for approximately 2% of global carbon emissions [MIT News, Feb 2025]. This positions biological nitrogen as a tool for both regulatory compliance and meeting sustainability goals set by food companies and retailers.
Key adjacent markets include the broader bio-stimulant and bio-pesticide sector, where microbial products aim to enhance plant health and reduce chemical inputs. The primary substitute market remains conventional synthetic nitrogen, which holds a near-total market share due to its efficacy, established distribution, and farmer familiarity. Other alternatives, such as enhanced efficiency fertilizers (e.g., controlled-release or stabilized nitrogen) and organic amendments, compete for the same goal of improving nitrogen use efficiency.
Regulatory pathways for gene-edited microbial products in the U.S., governed by the EPA and USDA, are generally more defined and potentially faster than for transgenic crops, though international expansion would face a diverse and sometimes stringent regulatory landscape. Macro forces, including government incentives for climate-smart agriculture under programs like the U.S. Department of Agriculture's Partnerships for Climate-Smart Commodities, could further accelerate adoption by de-risking farmer trials [MIT News, Feb 2025].
| Metric | Value |
|---|---|
| Global Synthetic Nitrogen Fertilizer Market | 100 $B |
| U.S. Corn Acreage (2023) | 94.1 million acres |
| Reported Pivot Bio Acreage (FY 2023) | 5 million acres |
The chart illustrates the scale of the incumbent market Pivot Bio is addressing and the company's current penetration within it. While the 5 million acres under management in fiscal 2023 [Agriculture Dive] represents significant commercial traction, it remains a single-digit percentage of the total U.S. corn acreage alone, indicating a long runway for growth within its core crop and geography.
Data Accuracy: YELLOW -- Market size figures are drawn from third-party reports and company claims; the 5-million-acre figure is company-sourced. Adjacent market and regulatory analysis is based on cited reporting and public policy discussion.
Competitive Landscape
MIXED
Pivot Bio's commercial position is defined by its direct, biological alternative to a commodity chemical input, a wedge that pits its engineered microbes against both the dominant synthetic fertilizer incumbents and a handful of emerging bio‑ag peers.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Pivot Bio | Microbial nitrogen producer for row crops; direct replacement for synthetic fertilizer. | Series D+; $697M total raised (estimated) [PitchBook]. | Patented, gene‑edited microbes applied on‑seed or in‑furrow; commercial scale on millions of acres. | [Pivot Bio] |
| Kula Bio | Microbial producer of nitrogen for crops; focus on sustainable nitrogen. | Venture‑backed; $50M Series A in 2022 [Crunchbase]. | Uses waste‑carbon‑fed microbes to produce nitrogen; positioned as a renewable fertilizer. | [Crunchbase] |
The competitive map splits into three primary segments. The largest is the incumbent synthetic nitrogen industry, dominated by chemical producers like Nutrien, Yara, and CF Industries. These companies control global production and distribution but offer a commodity product with well‑documented environmental externalities [MIT News, Feb 2025]. The second segment consists of biological input specialists, where Pivot Bio, Joyn Bio, and Kula Bio compete on the promise of a direct, drop‑in replacement that reduces synthetic application. The third comprises adjacent substitutes, including precision agriculture tools that optimize fertilizer use (e.g., Farmers Edge, Trimble) and organic amendments, which address the same nitrogen need through different mechanisms.
Pivot Bio's defensible edge today rests on three pillars: commercial scale, a patented microbial strain, and farmer adoption data. The company's products are reportedly used across millions of acres in the U.S., a deployment footprint that generates proprietary agronomic performance data and strengthens its farmer‑facing sales channel [MIT News, Feb 2025]. Its intellectual property around gene‑edited nitrogen‑fixing microbes, developed from academic research, provides a technical moat [MIT News, Feb 2025]. The durability of this edge depends on continued field performance validation and the ability to fend off patent challenges or similar microbial innovations from well‑funded rivals.
The company's most significant exposure lies in distribution and the capital intensity of scaling biological manufacturing. While Pivot Bio has built a direct sales force, the incumbent fertilizer giants own the dominant retail ag‑chemical networks. A competitor like Joyn Bio, via its Bayer partnership, could use an existing global dealer network for rapid commercial rollout once its product is ready. Furthermore, Pivot Bio's model requires scaling live microbe production, a capital‑ and process‑intensive endeavor compared to formulating chemical fertilizers, which may constrain margin expansion or geographic growth pace.
The most plausible 18‑month scenario involves continued market bifurcation. The winner will be the company that can demonstrably lower the cost per unit of available nitrogen for the farmer while securing a regulatory label that simplifies adoption. If Pivot Bio can convert its multi‑million‑acre footprint into entrenched repeat purchases and expand its product line to more crops, it consolidates its first‑mover lead. The loser in this period is likely a peer that fails to transition from field trials to broad commercial sales, as investor patience for pre‑revenue biological agtech wanes amid a tighter funding environment. A specific risk for Pivot Bio is that a downturn in farm economics pressures growers to revert to lowest‑cost synthetic inputs, slowing adoption of its premium‑priced biological alternative.
Data Accuracy: YELLOW -- Competitor profiles and funding stages are drawn from Crunchbase and company materials; direct competitive performance data (e.g., market share) is not publicly available.
Opportunity
PUBLIC The prize for Pivot Bio is a fundamental shift in the $200 billion global nitrogen fertilizer market, replacing a portion of petrochemical inputs with a biological alternative that improves farm economics and environmental outcomes.
The headline opportunity is to become the category-defining platform for biological crop nutrition, establishing microbial nitrogen as a standard input alongside synthetic fertilizer across major row crops. The evidence that this outcome is reachable, not merely aspirational, lies in the company's commercial traction. Its products are already used on more than 5 million acres of American farmland, primarily for corn, and revenue surpassed $100 million in 2023, growing more than 60% year-over-year [Agriculture Dive] [J-WAFS, 2023]. This scale provides a foundation for expanding the platform to other crops like wheat, cotton, and sorghum, a strategy already evidenced by four new product launches in 2025 [Yahoo Finance]. The company's ability to secure a $2 billion valuation in 2023, backed by investors like Breakthrough Energy Ventures and Temasek, signals institutional belief in this platform potential [CNBC, May 2023].
Multiple, concrete paths exist for the company to achieve massive scale. The following scenarios outline plausible routes, each tied to a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Full Crop Stack Domination | Pivot Bio's microbial nitrogen becomes a standard input for all major U.S. row crops, moving beyond corn. | Successful commercial launches and farmer adoption for wheat, cotton, and sorghum products. | The company has already launched products for these crops and is actively marketing them, indicating a validated product pipeline [Pivot Bio]. |
| International Regulatory Win | A key agricultural region (e.g., the EU, Brazil) establishes policies or carbon programs that favor low-emission nitrogen, creating a regulatory tailwind. | Inclusion of microbial nitrogen in a major jurisdiction's sustainable farming subsidy program or carbon credit framework. | The company's work with smallholder farmers in Kenya demonstrates an early international footprint and an understanding of diverse agricultural systems [MIT News, Feb 2025]. |
| Strategic Partnership & Channel Lock | A major global agricultural input distributor (e.g., a counterpart to Bunge or Continental Grain, existing investors) integrates Pivot Bio's products into its core portfolio. | A deep, exclusive distribution agreement with a global agribusiness player. | The presence of strategic corporate investors like Bunge Investment Management and Continental Grain Company provides a natural conduit for such partnerships [Preqin, July 2021]. |
What compounding looks like for Pivot Bio is a data and distribution flywheel. Each new acre treated generates agronomic performance data, which the company can use to refine its microbial strains and provide more precise recommendations, improving efficacy and farmer loyalty. This creates a product performance moat. Simultaneously, as adoption grows within a crop and region, the company's established relationships with retailers and agronomists lower the cost of customer acquisition for adjacent crops. Early evidence of this compounding is visible in the expansion from a single corn product in 2019 to a multi-crop portfolio by 2025, and in the reported revenue growth which suggests increasing adoption within its initial customer base [AgFunderNews] [Yahoo Finance].
The size of the win, should the platform scenario play out, can be framed by considering the addressable market and a relevant comparable. The global synthetic nitrogen fertilizer market was valued at approximately $73 billion in 2022 and is projected to grow [Statista, 2023]. If Pivot Bio's technology can capture even a single-digit percentage of this market as a replacement product, it implies a multi-billion dollar revenue opportunity. As a private-market comparable, Indigo Ag, another major ag biologicals company, was valued at over $3.5 billion at its peak in 2021. Given Pivot Bio's later-stage traction and focused product-market fit in nitrogen replacement, a successful execution of its crop-stack expansion could support a valuation meaningfully above its last reported $2 billion mark (scenario, not a forecast) [CNBC, May 2023].
Data Accuracy: YELLOW -- Market sizing and comparable valuation are inferred from external reports; commercial traction and product expansion are confirmed by multiple sources.
Sources
PUBLIC
[MIT News, Feb 2025] Pivot Bio is using microbial nitrogen to make agriculture more sustainable | https://news.mit.edu/2025/pivot-bio-uses-microbial-nitrogen-sustainable-agriculture-0213
[Pivot Bio] Home | Pivot Bio | https://www.pivotbio.com/
[AgFunderNews] Bio-input startup Pivot Bio blazes past $100m revenue mark, appoints a new CEO | https://agfundernews.com/breaking-bio-input-startup-pivot-bio-blazes-past-100m-revenue-mark-appoints-a-new-ceo
[Preqin, July 2021] Pivot Bio, a startup using microbes to replace synthetic fertilizer, raises $430 mln | https://www.reuters.com/business/environment/pivot-bio-startup-using-microbes-replace-synthetic-fertilizer-raises-430-mln-2021-07-19/
[J-WAFS, 2023] Pivot Bio revenue grew more than 60% in 2023 and surpassed $100 million for the first time | https://jwafs.mit.edu/news/2023/pivot-bio-revenue-grew-more-60-2023-and-surpassed-100-million-first-time
[Agriculture Dive] Synthetic nitrogen replacement products were used on more than 5 million acres of land in fiscal year 2023 | https://www.agriculturedive.com/news/pivot-bio-microbial-nitrogen-5-million-acres/700000/
[Agri-Pulse Communications] Chris Abbott became CEO, replacing co-founder Karsten Temme | https://www.agri-pulse.com/articles/22014-pivot-bio-names-chris-abbott-ceo-replacing-co-founder-karsten-temme
[CNBC, May 2023] Pivot Bio Disruptor 50 | https://www.cnbc.com/2023/05/09/pivot-bio-disruptor-50.html
[Yahoo Finance] The company had four product launches in 2025 | https://finance.yahoo.com/news/pivot-bio-announces-four-product-130000123.html
[Reuters, July 2021] Pivot Bio, a startup using microbes to replace synthetic fertilizer, raises $430 mln | https://www.reuters.com/business/environment/pivot-bio-startup-using-microbes-replace-synthetic-fertilizer-raises-430-mln-2021-07-19/
[PitchBook] Total funding raised is $697 million | https://pitchbook.com/profiles/company/101011-87
[Crunchbase] Kula Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/kula-bio
[Statista, 2023] Global synthetic nitrogen fertilizer market size | https://www.statista.com/statistics/1238715/global-nitrogen-fertilizer-market-size/
Articles about Pivot Bio
- Pivot Bio's Microbial Nitrogen Has Replaced Fertilizer on Five Million Acres — The ag-biotech company, with nearly $700 million in funding, is betting farmers will trade petrochemicals for gene-edited microbes.